Profile data is unavailable for this security.
About the company
PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
- Revenue in USD (TTM)0.00
- Net income in USD-8.98m
- Incorporated1996
- Employees2.00
- LocationPharmaCyte Biotech Inc3960 Howard Hughes Parkway, Suite 500LAS VEGAS 89169United StatesUSA
- Phone+1 (917) 595-2850
- Fax+1 (917) 595-2851
- Websitehttps://pharmacyte.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Brainstorm Cell Therapeutics Inc | 0.00 | -10.85m | 5.89m | 27.00 | -- | -- | -- | -- | -1.50 | -1.50 | 0.00 | -0.6973 | 0.00 | -- | -- | 0.00 | -637.06 | -112.30 | -- | -219.11 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 32.39 | -- | -- | -- |
| enVVeno Medical Corp | 0.00 | -21.97m | 6.11m | 37.00 | -- | 0.1829 | -- | -- | -37.84 | -37.84 | 0.00 | 50.98 | 0.00 | -- | -- | 0.00 | -53.09 | -52.36 | -56.24 | -55.28 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.22 | -- | -36.69 | -- |
| Alzamend Neuro Inc | 0.00 | -6.47m | 6.20m | 4.00 | -- | 1.42 | -- | -- | -5.71 | -5.71 | 0.00 | 1.15 | 0.00 | -- | -- | 0.00 | -116.49 | -171.97 | -144.76 | -256.71 | -- | -- | -- | -- | -- | -766.93 | 0.00 | -- | -- | -- | 48.68 | -- | -- | -- |
| Aptorum Group Ltd | -100.00bn | -100.00bn | 6.37m | 1.00 | -- | 0.2482 | -- | -- | -- | -- | -- | 3.15 | -- | -- | -- | -- | -- | -33.06 | -- | -31.53 | -- | 1.65 | -- | -1,009.86 | -- | -- | 0.2079 | -- | -100.00 | -- | -51.09 | -- | -- | -- |
| Mustang Bio Inc | 0.00 | -2.34m | 6.38m | 6.00 | -- | 0.653 | -- | -- | -47.37 | -47.37 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -17.59 | -70.16 | -224.95 | -83.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 69.47 | -- | -- | -- |
| Theriva Biologics Inc | 0.00 | -26.19m | 6.50m | 22.00 | -- | 0.2783 | -- | -- | -5.53 | -5.53 | 0.00 | 0.6539 | 0.00 | -- | -- | 0.00 | -73.83 | -37.94 | -99.55 | -42.02 | -- | -- | -- | -- | -- | -- | 0.2025 | -- | -- | -- | -39.81 | -- | -- | -- |
| Creative Medical Technology Holdings Inc | 6.00k | -5.96m | 6.50m | 4.00 | -- | 0.8584 | -- | 1,083.35 | -2.87 | -2.87 | 0.0027 | 2.17 | 0.0009 | 1.10 | -- | 1,500.00 | -93.58 | -83.62 | -98.14 | -- | 60.00 | 62.58 | -99,356.66 | -10,541.10 | 20.70 | -- | 0.00 | -- | 22.22 | -41.85 | -3.91 | -- | -- | -- |
| Aptevo Therapeutics Inc | 0.00 | -27.95m | 6.70m | 37.00 | -- | 0.296 | -- | -- | -306,220.00 | -306,220.00 | 0.00 | 22.67 | 0.00 | -- | -- | 0.00 | -125.64 | -47.17 | -172.77 | -82.66 | -- | -- | -- | -487.43 | -- | -- | 0.00 | -- | -- | -- | -29.38 | -- | -- | -- |
| Pharmacyte Biotech Inc | 0.00 | -8.98m | 6.90m | 2.00 | -- | 0.1297 | -- | -- | -1.32 | -1.32 | 0.00 | 5.38 | 0.00 | -- | -- | 0.00 | -12.74 | 7.21 | -13.51 | 7.54 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 235.53 | -- | -- | -- |
| Synlogic Inc | 0.00 | -3.23m | 7.27m | 1.00 | -- | 0.7042 | -- | -- | -0.2625 | -0.2625 | 0.00 | 0.8826 | 0.00 | -- | -- | 0.00 | -17.30 | -44.41 | -27.54 | -50.06 | -- | -- | -- | -3,944.49 | -- | -- | 0.00 | -- | -99.76 | -67.55 | 61.88 | -- | -59.28 | -- |
| Aclarion Inc | 67.48k | -7.39m | 7.36m | 6.00 | -- | 0.1202 | -- | 109.13 | -1,687.50 | -1,687.50 | 0.1948 | 21.46 | 0.0082 | -- | 2.76 | 11,246.67 | -89.50 | -- | -97.72 | -- | -7.85 | -- | -10,868.49 | -- | -- | -25,428.22 | 0.00 | -- | -39.36 | -- | -43.60 | -- | -- | -- |
| Kiora Pharmaceuticals Inc | 0.00 | -8.54m | 7.65m | 12.00 | -- | 0.3187 | -- | -- | -2.05 | -2.05 | 0.00 | 6.53 | 0.00 | -- | -- | 0.00 | -24.99 | -48.77 | -27.44 | -56.18 | -- | -- | -- | -276.73 | -- | -- | 0.00 | -- | -- | 42.93 | 127.56 | -- | -- | -- |
| Curative Biotechnology Inc | 0.00 | -6.02m | 7.75m | 4.00 | -- | -- | -- | -- | -0.0105 | -0.0105 | 0.00 | -0.0018 | 0.00 | -- | -- | 0.00 | -339.98 | -- | -- | -- | -- | -- | -- | -- | -- | -5.51 | -- | -- | -- | -- | -302.92 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to PharmaCyte Biotech Inc's reporting currency: US Dollar USD
6.36%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| HRT Financial LPas of 31 Dec 2025 | 182.80k | 1.80% |
| Geode Capital Management LLCas of 31 Dec 2025 | 123.84k | 1.22% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 94.04k | 0.93% |
| Equitec Proprietary Markets LLCas of 30 Sep 2025 | 82.73k | 0.82% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 51.47k | 0.51% |
| Schonfeld Strategic Advisors LLCas of 30 Sep 2025 | 26.20k | 0.26% |
| Simplex Trading LLCas of 31 Dec 2025 | 25.83k | 0.26% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 23.45k | 0.23% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2025 | 19.21k | 0.19% |
| Citadel Securities LLCas of 30 Sep 2025 | 14.53k | 0.14% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
